Oral composition
An oral composition combining pyrroloquinoline quinone with non-heme iron and additional components activates mitochondria, enhancing vitality, skin health, and protein metabolism by increasing ATP production.
Patent Information
- Application Number
- JP2025077746
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Filing Date
- 2025-05-08
- Publication Date
- 2026-11-19
AI Technical Summary
There is a lack of research on oral compositions combining pyrroloquinoline quinone with other components to achieve desired health benefits.
An oral composition containing pyrroloquinoline quinone and non-heme iron, optionally combined with polyphenols, alpha-lipoic acid, carnitine, plants like grapes and lingonberries, and lactic acid bacteria, formulated to activate mitochondria and enhance energy production.
The composition exhibits effects such as maintaining and improving vitality, skin health, and promoting protein metabolism by activating mitochondria and increasing ATP production.
Smart Images

Figure 2026181924000001 
Figure 2026181924000002 
Figure 2026181924000003
Abstract
Description
Technical Field
[0001] The present invention relates to an oral composition containing pyrroloquinoline quinone and iron.
Background Art
[0002] In recent years, against the backdrop of growing interest in health and the like, various health foods have been developed, and research on various materials used in health foods has been conducted.
[0003] For example, pyrroloquinoline quinone (PQQ) has been suggested to be a potential new vitamin and has attracted attention (for example, Non-Patent Document 1). Pyrroloquinoline quinone is known to have many physiological activities such as active oxygen and radical scavenging action, cell proliferation promoting action, ultraviolet absorbing action, nerve growth factor production promoting action, brain function improving action, hair growth promoting action, complexion improving action, melanin production inhibiting and whitening action, and mitochondrial activation action, and its use as an active ingredient in pharmaceuticals, quasi-drugs, cosmetics or health supplements is expected (for example, Patent Documents 1 and 2).
[0004] Further, as a study on an oral composition combining pyrroloquinoline quinone with other components, for example, it has been reported that combining sesamins and pyrroloquinoline quinone improves mitochondrial function and / or mitochondrial energy production capacity more effectively than treating each of them alone (Patent Document 3).
Prior Art Documents
Patent Documents
[0005]
Patent Document 1
Patent Document 2
Patent Document 3
Non-Patent Documents
[0006] [Non-Patent Document 1] Nature, 422, p832, 2003 [Overview of the Initiative] [Problems that the invention aims to solve]
[0007] As mentioned above, although some studies have been conducted on pyrroloquinoline quinone, there has been little research on oral compositions combining pyrroloquinoline quinone with other components.
[0008] The object of the present invention is to provide an oral composition containing pyrroloquinoline quinone and iron that produces a desired effect. [Means for solving the problem]
[0009] The inventors of this invention diligently studied to solve the above problems and found that the desired effect could be achieved by combining pyrroloquinoline quinone and iron, thus completing the present invention.
[0010] In other words, the present invention is as follows: [1] An oral composition containing pyrroloquinoline quinone and iron. [2] The oral composition according to [1], characterized in that the iron is non-heme iron. [3] The oral composition according to [1] or [2] further comprising at least one selected from the group consisting of (a) to (e) below. (a) At least one polyphenol selected from resveratrol and ellagic acid (b) α-lipoic acid (c) Carnitine (d) At least one plant selected from grapes and lingonberries (e) Lactic acid bacteria [4] The oral composition according to [1] or [2], wherein the iron content in the oral composition is 1.5 to 5% by mass on a dry weight basis. [5] The oral composition described in [4], which is a tablet. [Effects of the Invention]
[0011] The oral composition of the present invention exhibits excellent effects such as maintaining and improving vitality, maintaining the health of the skin or mucous membranes, and promoting protein metabolism. [Modes for carrying out the invention]
[0012] The oral composition of the present invention is characterized by containing pyrroloquinoline quinone and iron.
[0013] The oral composition of the present invention, through a combination of pyrroloquinoline quinone and iron, can activate mitochondria and increase the production of adenosine triphosphate (ATP). As a result, it exhibits excellent effects such as maintaining and improving vitality, maintaining the health of the skin or mucous membranes, and promoting protein metabolism.
[0014] Here, ATP, which is energy, is necessary for cells to function. Approximately 90% of this ATP is produced by oxidative phosphorylation in mitochondria in almost all cells except red blood cells. Therefore, it is thought that promoting mitochondrial activity, which is a common energy production mechanism regardless of cell type, can lead to the maintenance and improvement of various cell functions. Specifically, these effects include maintaining and improving vitality, maintaining the health of the skin or mucous membranes, and promoting protein metabolism.
[0015] For example, neuronal cell death, a contributing factor to decreased vitality, is known to be induced by decreased mitochondrial activity (Kitagawa, Kazuo, et al. "Results and Clinical Applications of Neuronal Cell Death Research." Stroke 30.6(2008):862-868). Therefore, promoting mitochondrial activity is thought to help maintain and improve vitality.
[0016] It is known that in epidermal cells, promotion of mitochondrial activity enhances the production of fibroblast growth factor (FGF) and epidermal growth factor (EGF) (Kazuhiko Hondō. "Cytological Effects of Plant Fermented Paste AO via Mitochondria and Antioxidant Action." Pharmacology and Therapy 45.7 (2017): 1141-1152.). It is also known that in airway epithelial cells, decreased mitochondrial activity causes excessive mucin secretion and the like (Aguilera-Aguirre, Leopoldo, et al. "Mitochondrial dysfunction increases allergic airway inflammation." The Journal of Immunology 183.8 (2009): 5379-5387.). Therefore, promotion of mitochondrial activity is considered to contribute to maintaining the health of the skin or mucosa.
[0017] Furthermore, it has been reported that promoting mitochondrial activity in muscle cells increases muscle weight (Ken Sugimoto. "3. Significance of Skeletal Muscle Mitochondrial Function and Myokine in Sarcopenia." Japanese Journal of Geriatrics 49.2 (2012): 199-202.). Therefore, promotion of mitochondrial activity is considered to contribute to promoting protein metabolism.
[0018] Therefore, the oral composition of the present invention can be used as an oral composition for maintaining and enhancing vitality, an oral composition for maintaining the health of skin or mucosa, and an oral composition for promoting protein metabolism.
[0019] Hereinafter, each component contained in the oral composition of the present invention will be described.
[0020] [Pyrroloquinoline quinone] The pyrroloquinoline quinone (hereinafter sometimes referred to as PQQ) in the present invention may be an oxidized form (oxidized PQQ) represented by the following formula (1), or a reduced form (reduced PQQ) represented by the following formula (2).
[0021] [Chemical Formula]
[0022] [ka]
[0023] Furthermore, the pyrroloquinoline quinone in the present invention may be in the form of a free form or a salt. Examples of pyrroloquinoline quinone salts include alkali metal salts, alkaline earth metal salts, and ammonium salts. The pyrroloquinoline quinone contained in the oral composition of the present invention can be extracted and purified from plants or fermented foods, or chemically synthesized, and commercially available products may also be used. Pyrroloquinoline quinone is found, for example, in plants such as parsley and bell peppers, and in fermented foods such as natto, tofu, and miso. Alternatively, plants or fermented foods containing pyrroloquinoline quinone may be used as is, after being powdered or granulated. When using plant extracts as pyrroloquinoline quinone, the extract may be in liquid form, but it can also be used in paste form or dried powder (extract powder). Examples of solvents used for extraction include water; lower alcohols such as methanol, ethanol, isopropanol, and butanol; lower esters such as ethyl acetate and methyl acetate; acetone; and mixed solvents of these with water. Among these, water, ethanol, or aqueous ethanol are preferred, and ethanol or aqueous ethanol are particularly preferred, as they allow for more effective enjoyment of the effects of the present invention. Furthermore, commercially available pyrroloquinoline quinone may be used. The amount of pyrroloquinoline quinone can be measured using high-performance liquid chromatography (HPLC).
[0024] The amount of pyrroloquinoline quinone in the oral composition of the present invention may be appropriately included within a range that achieves its effect. For example, the oral composition of the present invention preferably contains 0.001 to 50% by mass of pyrroloquinoline quinone on a dry weight basis, more preferably 0.005 to 20% by mass, and even more preferably 0.01 to 10% by mass.
[0025] [iron] In this invention, iron can be naturally derived, obtained by extraction and purification from plants, animals, fish, minerals, etc., or synthesized using chemical or enzymatic reactions. Furthermore, heme iron, which is an iron polyferrin complex bound to a protein (peptide), or non-heme iron may be used. Examples of non-heme iron include iron salts such as ferric chloride, ferric chloride, sodium ferrous citrate, iron citrate, ammonium iron citrate, ferrous gluconate, ferric oxide, sodium iron chlorophyllin, iron lactate, ferric pyrophosphate, ferrous fumarate, iron sulfate, and ferrous sulfate. In this invention, non-heme iron is preferred, and sodium ferrous citrate and ferric pyrophosphate are more preferred, as they better achieve the effects of the present invention. Only one type of iron may be used, or two or more types may be mixed. Commercially available iron may also be used.
[0026] The amount of iron in the oral composition of the present invention may be appropriately included within the range that achieves its effect. For example, the oral composition of the present invention preferably contains 0.001 to 50% by mass of iron on a dry weight basis, more preferably 0.01 to 20% by mass, even more preferably 0.1 to 10% by mass, and particularly preferably 1.5 to 5% by mass.
[0027] Regarding the mass ratio of iron to pyrroloquinoline quinone, in order to better enjoy the effects of the present invention, it is preferable that the ratio of pyrroloquinoline quinone to iron is 1:0.001 to 1000, more preferably 1:0.005 to 500, even more preferably 1:0.01 to 100, and particularly preferably 1:0.1 to 10.
[0028] The daily intake of the components of the present invention (pyrroloquinoline quinone and iron) for adults is not particularly limited, but from the viewpoint of enjoying the effects of the present invention, it is preferably 0.0001 to 100 mg, more preferably 0.001 to 50 mg, even more preferably 0.005 to 10 mg, and particularly preferably 0.01 to 1 mg in terms of dry mass.
[0029] The oral composition of the present invention preferably contains, in addition to pyrroloquinoline quinone and iron, at least one selected from the group consisting of (a) to (e) below. (a) At least one polyphenol selected from resveratrol and ellagic acid (b) α-lipoic acid (c) Carnitine (d) At least one plant selected from grapes and lingonberries (e) Lactic acid bacteria
[0030] [Resveratrol] The resveratrol used in this invention is a type of stilbenoid (stilbene derivative) polyphenol, and is not particularly limited as long as it is a compound with the systematic name 3,5,4'-trihydroxy-trans-stilbene. Resveratrol is found in natural products such as grapes, lingonberries, cranberries, and Indian kinothus. In the compositions of this invention, processed products of such natural products (dried products, pulverized products, juices, extracts, purified products, etc.) may be used, or chemically synthesized products may be used.
[0031] Resveratrol may be used alone or in combination of two or more of the above-mentioned types. Furthermore, there are no particular limitations on the species or group of plants from which resveratrol is derived; it can be appropriately selected according to the purpose. For example, lingonberries are suitable for use due to their high resveratrol content. Grapes are even more preferable because they contain other resveratrols (oligostilbenes) in addition to trans-resveratrol, and a synergistic effect has been confirmed. Commercially available resveratrol may also be used.
[0032] In the oral composition of the present invention, if resveratrol is included, the amount may be appropriately included within a range that provides the desired effect. For example, it is preferable that the oral composition of the present invention contains 0.001 to 50% by mass of resveratrol on a dry weight basis, more preferably 0.005 to 20% by mass, and even more preferably 0.01 to 10% by mass.
[0033] In the composition of the present invention, if resveratrol is included, the mass ratio of resveratrol to pyrroloquinoline quinone is preferably 1:0.001 to 1000, more preferably 1:0.005 to 500, even more preferably 1:0.01 to 100, and particularly preferably 1:0.1 to 10, in order to better enjoy the effects of the present invention.
[0034] Furthermore, when resveratrol is included, the effects of the present invention can be more fully enjoyed, so the daily intake of resveratrol for adults according to the present invention is preferably 0.0001 to 100 mg, more preferably 0.001 to 50 mg, even more preferably 0.005 to 10 mg, and particularly preferably 0.01 to 1 mg, in terms of dry mass.
[0035] [Alpha-lipoic acid] The alpha-lipoic acid used in this invention is a type of fatty acid also known as thioctic acid. It is amphiphilic and soluble in both water and oil. Therefore, it can act in both the aqueous phase cytoplasm (such as blood and cytoplasm) and the oil phase cell membrane (the lipid portion of the cell membrane), becoming an antioxidant that is active throughout the body. Alpha-lipoic acid is also known as one of the coenzymes that function in mitochondria, a cellular organelle, and is known to directly act on and promote the activation of the citric acid cycle. Furthermore, commercially available alpha-lipoic acid may be used.
[0036] In the oral composition of the present invention, if α-lipoic acid is included, its content may be appropriately included within a range that achieves its effect. For example, it is preferable that the oral composition of the present invention contains 0.0001 to 10% by mass of α-lipoic acid on a dry weight basis, more preferably 0.001 to 8% by mass, even more preferably 0.001 to 6% by mass, and particularly preferably 0.01 to 5% by mass.
[0037] In the composition of the present invention, when α-lipoic acid is included, the mass ratio of α-lipoic acid to pyrroloquinoline quinone is preferably 1:0.001 to 1000, more preferably 1:0.005 to 500, even more preferably 1:0.01 to 100, and particularly preferably 1:0.1 to 10, in order to better enjoy the effects of the present invention.
[0038] Furthermore, when alpha-lipoic acid is included, the effects of the present invention can be more fully enjoyed. Therefore, the daily intake of alpha-lipoic acid for adults is preferably 0.0001 to 100 mg, more preferably 0.001 to 50 mg, even more preferably 0.005 to 10 mg, and particularly preferably 0.01 to 1 mg, based on dry mass.
[0039] [Carnitine] In this invention, carnitine plays a role in transporting fatty acids to the mitochondria, the site of β-oxidation, when lipids are burned in the body to produce energy. Carnitine is abundant in skeletal muscle and cardiac muscle, and plays an important role in lipid metabolism, such as the transfer of long-chain fatty acids released in muscle cells to mitochondria. In this invention, carnitine is a concept that includes carnitine salts and carnitine derivatives. Examples include L-carnitine, DL-carnitine, and acetyl-L-carnitine, and these may be used individually or in combination of two or more. In this invention, it is preferable to use L-carnitine. In addition, as carnitine, inorganic salts such as intramolecular salts, hydrochloride salts, and sodium salts, or organic salts such as tartrate, oxalate, and fumarate may be used. In addition, commercially available carnitine products may be used.
[0040] In the oral composition of the present invention, if carnitine is included, the amount may be appropriately included within a range that provides the desired effect. For example, it is preferable that the oral composition of the present invention contains 0.0001 to 10% by mass of carnitine on a dry weight basis, more preferably 0.001 to 8% by mass, even more preferably 0.001 to 6% by mass, and particularly preferably 0.01 to 5% by mass.
[0041] In the composition of the present invention, when carnitine is included, the mass ratio of carnitine to pyrroloquinoline quinone is preferably 1:0.001 to 1000, more preferably 1:0.005 to 500, even more preferably 1:0.01 to 100, and particularly preferably 1:0.1 to 10, in order to better enjoy the effects of the present invention.
[0042] Furthermore, when carnitine is included, the effects of the present invention can be more fully enjoyed, so the daily intake of carnitine for adults according to the present invention is preferably 0.0001 to 100 mg, more preferably 0.001 to 50 mg, even more preferably 0.005 to 10 mg, and particularly preferably 0.01 to 1 mg, in terms of dry mass.
[0043] [Ellagic acid] Ellagic acid is a type of natural phenolic compound that exists in a free state, but is more often found as one of the components of tannins called ellagitannins. The ellagic acid used in this invention is not particularly limited as long as it can be used as a food product, and can be used as is from plants, or obtained by extraction, purification, or synthesis. When using plant-derived ellagic acid, examples of the plants from which it may be derived include strawberries, raspberries, and pomegranates. Furthermore, the ellagic acid used in this invention may be in the form of anhydrous or hydrate such as a monohydrate. In this invention, if ellagic acid is in the form of a hydrate, the amount of ellagic acid referred to herein shall be on an anhydrous basis. Furthermore, commercially available ellagic acid may be used.
[0044] In the oral composition of the present invention, if ellagic acid is included, its content may be appropriately included within a range that achieves its effect. For example, it is preferable that the oral composition of the present invention contains 0.001 to 50% by mass of ellagic acid on a dry weight basis, more preferably 0.005 to 20% by mass, and even more preferably 0.01 to 10% by mass.
[0045] In the composition of the present invention, when ellagic acid is contained, the mass ratio of ellagic acid to pyrroloquinoline quinone is preferably 1:0.001 to 1000, more preferably 1:0.005 to 500, even more preferably 1:0.01 to 100, and particularly preferably 1:0.1 to 10, in order to better enjoy the effects of the present invention.
[0046] Furthermore, when ellagic acid is included, the effects of the present invention can be more fully enjoyed, so the daily intake of ellagic acid for adults is preferably 0.0001 to 100 mg, more preferably 0.001 to 50 mg, even more preferably 0.005 to 10 mg, and particularly preferably 0.01 to 1 mg, based on dry mass.
[0047] [Grapes] In this invention, the grapes are plants belonging to the Vitaceae family, and while the fruit, skin, seeds, leaves, etc., may be used, they are not particularly limited, but the fruit, seeds, or leaves are preferred. Furthermore, the grapes used are not particularly limited, and any variety may be used, such as European and American varieties (scientific name: Vitis vinifera) or American varieties (scientific name: Vitis labrusca), but European and American varieties are preferred. In particular, red grapes of European and American varieties with red, purple, blue, dark blue, or nearly black skin and red flesh are preferred. Processed products of grapes may also be used as grapes, for example, dried and crushed harvested grapes into a powder, or extracts (extract powder) extracted with water, lower alcohol, or a mixture thereof, or fermented products (fermented powder) may be used, and the use of extract powder is preferred. As for the grapes used in this invention, extract powder of grape fruit, seeds, or leaves is preferred in order to better enjoy the effects of this invention, and extract powder of grape seeds is particularly preferred. In addition, commercially available grapes may be used as grapes.
[0048] In the oral composition of the present invention, if grapes are included, the amount may be appropriately included within a range that achieves the desired effect. For example, it is preferable that the oral composition of the present invention contains 0.001 to 50% by mass of grapes on a dry weight basis, more preferably 0.005 to 20% by mass, and even more preferably 0.01 to 10% by mass.
[0049] In the composition of the present invention, when grapes are included, the mass ratio of grapes to pyrroloquinoline quinone is preferably 1:0.001 to 1000, more preferably 1:0.005 to 500, even more preferably 1:0.01 to 100, and particularly preferably 1:0.1 to 10, in order to better enjoy the effects of the present invention.
[0050] Furthermore, when grapes are included, the effects of the present invention can be more fully enjoyed, so the daily intake of grapes according to the present invention for adults is preferably 0.0001 to 100 mg, more preferably 0.001 to 50 mg, even more preferably 0.005 to 10 mg, and particularly preferably 0.01 to 1 mg, in terms of dry mass.
[0051] [Lingonberry] In this invention, lingonberry (Vaccinium vitis-idaea L.) is an evergreen shrub belonging to the genus Vaccinium in the family Ericaceae. The fruit, bark, seeds, leaves, etc., can be used, and are not particularly limited, but the fruit is preferred. The lingonberry used in this invention can be fresh or dried, and lingonberry extract may also be used. The method for producing lingonberry extract is not particularly limited and can be produced according to methods commonly used in the art, for example, by extracting the raw materials for the extract. Examples of extraction methods, though not limited, include hot water extraction, ultrasonic extraction, filtration, reflux extraction, and solvent (e.g., ethanol) extraction. Methods for producing extract without extraction, though not limited, include fruit juicing and concentration, and can be carried out by any method commonly used in the art. Furthermore, commercially available lingonberries may be used.
[0052] In the oral composition of the present invention, if lingonberry is included, the amount may be appropriately included within a range that produces the desired effect. For example, it is preferable that the oral composition of the present invention contains lingonberry in an amount of 0.001 to 50% by mass on a dry weight basis, more preferably 0.005 to 20% by mass, and even more preferably 0.01 to 10% by mass.
[0053] In the composition of the present invention, if lingonberry is included, the mass ratio of lingonberry to pyrroloquinoline quinone is preferably 1:0.001 to 1000, more preferably 1:0.005 to 500, even more preferably 1:0.01 to 100, and particularly preferably 1:0.1 to 10, in order to better enjoy the effects of the present invention.
[0054] Furthermore, when lingonberries are included, the effects of the present invention can be more fully enjoyed, so the daily intake of lingonberries for adults according to the present invention is preferably 0.0001 to 100 mg, more preferably 0.001 to 50 mg, even more preferably 0.005 to 10 mg, and particularly preferably 0.01 to 1 mg, in terms of dry mass.
[0055] [Lactic acid bacteria] The lactic acid bacteria of this invention refer to bacteria that produce lactic acid through metabolism. The lactic acid bacteria that can be used in this invention may be live or dead, and in the case of dead bacteria, they may be lysates of the bacterial cells. Lactic acid bacteria powder can be obtained, for example, by removing unnecessary components such as the culture medium from cultured lactic acid bacteria or a lactic acid bacteria culture used for fermentation, and then pulverizing the bacterial cells of the lactic acid bacteria by a known method. The type of lactic acid bacteria is not particularly limited as long as it produces lactic acid as a metabolite, and examples include those that have been conventionally taken orally by animals such as humans, such as those of the genera Bifidobacterium, Lactbacillus, Enterococcus, Leuconostoc, Pediococcus, Staphylococcus, Tetragenococcus, and Bacillus. You can use commercially available lactic acid bacteria. In the present invention, it is preferable to use spore-forming lactic acid bacteria. Spore-forming lactic acid bacteria are lactic acid bacteria that form spores and are characterized by their resistance to dryness, heat, and acid. Examples of spore-forming lactic acid bacteria include bacteria belonging to the genus Bacillus. In the present invention, from the viewpoint of demonstrating the excellent effects of the present invention, it is particularly preferable to use Bacillus coagulans (also called Weizmannia coagulans). Commercially available spore-forming lactic acid bacteria may also be used.
[0056] In the oral composition of the present invention, if lactic acid bacteria are included, the amount may be appropriately included within a range that achieves the desired effect. For example, it is preferable that the oral composition of the present invention contains lactic acid bacteria in an amount of 0.001 to 50% by mass on a dry weight basis, more preferably 0.005 to 20% by mass, and even more preferably 0.01 to 10% by mass.
[0057] In the composition of the present invention, when lactic acid bacteria are included, the mass ratio of lactic acid bacteria to pyrroloquinoline quinone is preferably 1:0.001 to 1000, more preferably 1:0.005 to 500, even more preferably 1:0.01 to 100, and particularly preferably 1:0.1 to 10, in order to better enjoy the effects of the present invention.
[0058] Furthermore, when lactic acid bacteria are included, the effects of the present invention can be more fully enjoyed. Therefore, the daily intake of the lactic acid bacteria of the present invention for adults is preferably 0.0001 to 100 mg, more preferably 0.001 to 50 mg, even more preferably 0.005 to 10 mg, and particularly preferably 0.01 to 1 mg, based on dry mass.
[0059] The oral composition of the present invention can be used, for example, as a pharmaceutical product (including quasi-drugs), a functional food such as a nutritional supplement, a functional food, or a food for specified health uses, for which efficacy claims have been approved by a designated institution, and other so-called health foods.
[0060] For example, since iron is recognized as a nutrient in functional foods, the oral composition of the present invention is useful as a functional food. Other nutritional components of functional foods besides iron include minerals such as potassium, calcium, and magnesium, and vitamins such as vitamin A, vitamin C, vitamin D, vitamin E, and vitamin K. The oral composition of the present invention can also be made into a functional food by adding these nutrients in addition to the components of the present invention (pyrroloquinoline quinone and iron).
[0061] As described above, the oral composition of the present invention can be used as an oral composition for maintaining and improving vitality. Such an oral composition for maintaining and improving vitality is not particularly limited as long as it contains the components of the present invention (pyrroloquinoline quinone and iron) and is used for maintaining or improving vitality, and can be distinguished from other products as a product. For example, any product that displays the function of maintaining and improving vitality on the product itself, packaging, instructions, or promotional materials (advertising media) is included within the scope of the present invention.
[0062] Specifically, examples include health foods that display phrases such as "maintain vitality," "keep vitality up," "support daily vitality," "suppress decline in vitality," "for those concerned about vitality," "boost vitality," "increase vitality," "vitality," and "vitality." Furthermore, functional foods include those whose functionality is based on the scientific evidence of maintaining or improving vitality.
[0063] The oral composition for maintaining and improving vitality of the present invention may display the components of the present invention as active ingredients, but is not limited to products in which the components of the present invention are displayed as active ingredients on the product packaging, etc. For example, the active ingredient may not be specified, and it may display pyrroloquinoline quinone or iron as the active ingredient, or it may display components other than pyrroloquinoline quinone and iron as the active ingredient. Furthermore, even general foods are included in the scope of the present invention if they are manufactured and sold with indications of their use. For example, foods that are sold with testimonials from people who have consumed them mentioning the maintenance and improvement of vitality, as recorded on websites, etc., are also included in the scope of the present invention.
[0064] Similarly, the oral composition of the present invention can be used as an oral composition for maintaining the health of the skin or mucous membranes. Such an oral composition for maintaining the health of the skin or mucous membranes is not particularly limited as long as it contains the components of the present invention (pyrroloquinoline quinone and iron) and is distinguishable from other products in that it is used for maintaining the health of the skin or mucous membranes. For example, any product in which the function of maintaining the health of the skin or mucous membranes is indicated on the product itself, packaging, instructions, or promotional materials (advertising media) is included within the scope of the present invention.
[0065] Specifically, examples include health foods that display claims such as "helps maintain the health of skin and mucous membranes," "maintains skin health," "supports the maintenance of skin and mucous membrane health," "keeps skin healthy," "improves skin condition," "maintains moisture in mucous membranes," and "maintains the barrier function of skin and mucous membranes." Furthermore, functional foods include those whose functionality is based on the scientific evidence of maintaining the health of skin or mucous membranes.
[0066] The oral composition for maintaining the health of the skin or mucous membranes of the present invention may be labeled as containing the components of the present invention as active ingredients, but is not limited to products in which the components of the present invention are labeled as active ingredients on the product packaging, etc. For example, the active ingredient may not be specified, or pyrroloquinoline quinone or iron may be labeled as the active ingredient, or components other than pyrroloquinoline quinone and iron may be labeled as the active ingredient. Furthermore, even general foods that are manufactured and sold with indications of their use are included in the scope of the present invention. For example, foods that are sold with testimonials from people who have consumed them mentioning the maintenance of skin or mucous membrane health on a website, etc., are also included in the scope of the present invention.
[0067] Similarly, the oral composition of the present invention can be used as an oral composition for promoting protein metabolism. Such an oral composition for promoting protein metabolism is not particularly limited as long as it contains the components of the present invention (pyrroloquinoline quinone and iron) and is distinguishable from other products in that it is used to promote protein metabolism. For example, any product that displays the function of promoting protein metabolism on the product itself, packaging, instructions, or promotional materials (advertising media) is included within the scope of the present invention.
[0068] Specifically, examples of health foods that display claims such as "supports protein absorption," "promotes muscle formation," "supports muscle maintenance," "keeps muscles healthy," "supports protein replenishment after exercise," "helps maintain muscle mass," and "contributes to maintaining health by being involved in protein metabolism" can be cited. Furthermore, functional foods include those whose scientific basis for functionality is the promotion of protein metabolism.
[0069] The oral composition for promoting protein metabolism of the present invention may display the components of the present invention as active ingredients, but is not limited to products in which the components of the present invention are displayed as active ingredients on the product packaging, etc. For example, the active ingredient may not be specified, or pyrroloquinoline quinone or iron may be displayed as the active ingredient, or components other than pyrroloquinoline quinone and iron may be displayed as the active ingredient. Furthermore, even general foods that are manufactured and sold with indications of their use are included in the scope of the present invention. For example, foods that are sold with testimonials from people who have consumed them mentioning the promotion of protein metabolism are also included in the scope of the present invention.
[0070] Examples of the oral composition of the present invention include tablets, capsules, powders, granules, liquids, granules, rods, plates, blocks, solids, rounds, pastes, creams, caplets, gels, chewable tablets, sticks, and the like. It may also be in the form of ice cream, jelly, cookies, cakes, chocolates, bottled beverages, etc. Among these, the forms of tablets, capsules, powders, granules, rounds, and chewable tablets are preferred, with tablets being particularly preferred.
[0071] When the oral composition of the present invention is made into tablets, pills, or chewable tablets, it is preferable to add one or more of the following: excipients, lubricants, and fluidizers. This improves moldability and enhances the storage stability of the manufactured product. In particular, the use of excipients and lubricants can further improve storage stability.
[0072] The oral composition of the present invention can be contained in one container, or divided into, for example, two or three containers, to represent one day's intake, so that the daily intake amount is the aforementioned intake.
[0073] The oral composition of the present invention may be prepared by known methods, with the addition of other components besides the components of the present invention as needed. Examples of other components include various excipients, binders, glossing agents, lubricants, stabilizers, diluents, fillers, thickeners, emulsifiers, antioxidants, pH adjusters, colorants, fragrances, and additives. [Examples]
[0074] The present invention will be described in more detail below with reference to examples. However, the scope of the present invention is not limited to these examples. Hereinafter, unless otherwise specified, "%" represents mass%.
[0075] <Test 1: Mitochondrial Activation Test> The ability of the oral composition of the present invention to activate mitochondria in normal human dermal fibroblasts (NHDF) was confirmed.
[0076] [Test substance] The following substances were used as test materials. • Pyrroloquinoline quinone: Commercially available pyrroloquinoline quinone disodium salt reagent • Sodium ferrous citrate: A commercially available reagent • Ferric pyrophosphate: Available in commercially available formulations • Heme iron: commercially available preparations • Resveratrol: A commercially available reagent • Alpha-lipoic acid: A commercially available reagent • L-carnitine: Commercially available L-carnitine tartrate reagent • Ellagic acid: A commercially available reagent • Grape seed extract: Dried powder of commercially available hydrated ethanol extract of grape seeds. • Lingonberry: Dried powder of commercially available lingonberry fruit juice • Spore-forming lactic acid bacteria: Dried powder of the spores of Bacillus coagulans, which is commercially available.
[0077] (Preparation of test substance) Each test substance was dissolved in 0.5% DMSO-10% FBS-DMEM medium, sterilized by passing through a 0.2 μm filter, and obtained as a test substance preparation solution. Using each test substance preparation solution, a culture medium containing the test substance was prepared by mixing them in the mass ratios shown in Table 2 so that the total concentration of the test substance in the culture medium was 1 μg / mL.
[0078] [Test Method] 75cm in a 37℃, 5V %CO2 incubator 2 Normal human dermal fibroblasts (NHDF) were cultured in 10% FBS-DMEM using flasks. The cells were then suspended by trypsin and placed in each well of a 96-well plate (collagen-coated) at a rate of 8 × 10⁶ cells. 3 Cells were seeded at a cell density of cells / well and pre-cultured for 24 hours in a 37°C, 5V %CO2 incubator.
[0079] After removing the culture medium from each well, 100 μL / well of culture medium containing the test substance was added, and the mixture was incubated at 37°C in a 5V %CO2 incubator for 24 hours.
[0080] After 24 hours of incubation, the culture medium was removed, and each well was washed twice with serum-free DMEM. Then, 50 μL of 1 μM Rhodamine 123 (manufactured by Fujifilm Wako Pure Chemical Industries), prepared with serum-free DMEM, was added to each well. After standing in a 37°C, 5V %CO2 incubator for 60 minutes, the reagents were removed and each well was washed twice with 200 μL of PBS. After removing PBS from each well, 200 μL of PBS was added to each well, and the fluorescence intensity (excitation wavelength Ex. 507 nm, fluorescence wavelength Em. 529 nm) was measured. Based on the obtained data, mitochondrial activity (% of control) was calculated. The relative values, with the Control (culture medium only) value set to 100, are shown in Tables 1 and 2.
[0081] %of control =(Data sample-Data blank) / (Data control-Data blank)×100
[0082] The denominator (baseline), "Data control - Data blank," is the value obtained by subtracting the fluorescence intensity of "blank" from the fluorescence intensity of the sample without the test substance (Control). On the other hand, the numerator, "Data sample - Data blank," is the value obtained by subtracting the fluorescence intensity of "blank" from the fluorescence intensity of the sample with the test substance added. Since the value obtained by subtracting the fluorescence intensity of blank from the fluorescence intensity of the sample is proportional to the amount of activated mitochondria, the calculated "% of control" serves as an indicator of mitochondrial activity.
[0083] [Table 1]
[0084] [Table 2]
[0085] As shown in Tables 1 and 2, the compositions of Examples 1 to 12 containing the components of the present invention (pyrroloquinoline quinone and iron) showed a synergistic improvement in mitochondrial activity compared to Comparative Examples 1 to 11, in which each test substance was added individually. Furthermore, in the compositions of Examples 4 to 12, which contained, in addition to the components of the present invention, at least one selected from the group consisting of resveratrol, α-lipoic acid, L-carnitine, ellagic acid, grape seed extract, lingonberry, and spore-forming lactic acid bacteria, higher mitochondrial activity was observed. Furthermore, in Comparative Example 12, which contained pyrroloquinoline quinone and resveratrol, which is known to have mitochondrial activating effects, no synergistic improvement in mitochondrial activity was observed. This indicates that even when components known to have mitochondrial activating effects are combined, a synergistic improvement in mitochondrial activity is not necessarily observed.
[0086] As described above, the oral composition of the present invention has been shown to have a high mitochondrial activation effect. Therefore, the oral composition of the present invention can be used to maintain and improve vitality, maintain the health of the skin or mucous membranes, and promote protein metabolism.
[0087] [tablet] After mixing the raw materials shown in Tables 3-12, tablets (oral composition for swallowing) with a tablet diameter of 8 mm and a dose of 300 mg per tablet were manufactured using a single-shot tablet press. Taking approximately 4 tablets per day yields effects such as maintaining and improving vitality, maintaining the health of the skin or mucous membranes, and promoting protein metabolism.
[0088] [Table 3]
[0089] [Table 4]
[0090] [Table 5]
[0091] [Table 6]
[0092] [Table 7]
[0093] [Table 8]
[0094] [Table 9]
[0095] [Table 10]
[0096] [Table 11]
[0097] [Table 12] [Industrial applicability]
[0098] The oral composition of the present invention is industrially useful because it can be used as a health food or the like.
Claims
1. An oral composition containing pyrroloquinoline quinone and iron.
2. The oral composition according to claim 1, characterized in that the iron is non-heme iron.
3. Furthermore, the oral composition according to claim 1 or 2, further comprising at least one selected from the group consisting of (a) to (e) below. (a) At least one polyphenol selected from resveratrol and ellagic acid (b) α-lipoic acid (c) Carnitine (d) At least one plant species selected from grapes and lingonberries (e) Lactic acid bacteria
4. The oral composition according to claim 1 or 2, wherein the iron content in the oral composition is 1.5 to 5% by mass on a dry weight basis.
Citation Information
Patent Citations
Skin agent for external use
JP1994100428A
Melanin production inhibitor and whitening dermal agent for external use
JP1996020512A
Composition containing sesamin and pqq
WO2021132077A1
